Download PDF
Thromb Haemost 1991; 65(01): 003-006
DOI: 10.1055/s-0038-1647443
Original Article
Schattauer GmbH Stuttgart

Fibrinolytic Activity in Chinese Patients with Diabetes or Hyperlipidemia in Comparison with Healthy Controls

Chao Hung Ho
1   The Division of Haematology, Department of lnternal Medicine, Veterans General Hospital, Taipei, Taiwan, R. O. C
,
Tjin Shing Jap
2   The Division of Endocrinology, Department of lnternal Medicine, Veterans General Hospital, Taipei, Taiwan, R. O. C
› Author Affiliations
Further Information

Publication History

Received 24 January 1990

Accepted after revision 03 August 1990

Publication Date:
02 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Plasma tissue-type plasminogen activator (tPA), plasminogen activator inhibitor (PAI) and euglobulin lysis time (ELT) were determined before and after the venous occlusion test (VOT) in 3 groups of patients with mean age about 60 years: 29 diabetic patients (D group), 8 hyperlipidemic patients (H group) and 19 healthy controls (C group). In the D and H groups, the mean of morning tPA was significantly higher than that of the C grogp, but the means of PAI were not significantly different among the 3 groups. ELI was significantly shortened and tPA was markedly increased after the VOT in all 3 groups whereas PAI had not significantly changed. In conclusion, high tPA activity and good fibrinolytic response without significant change of PAI .activity were found in the diabetic and hyperlipidemic patients, and no definite impairment of the fibrinolytic activity could be found in the Chinese patients with diabetes and hyperlipidemia. This might be one of the reasons why the Chinese has low incidence of thromboembolic diseases.

 

  • References

  • 1 Bick RL. Hypercoagulability and thrombosis. In: Basic Concepts of Hemostasis and Thrombosis Murano G, Bick RL. (eds). CRC Press; Boca Raton, FL: 1983: 31
  • 2 Rabkin SW, Sackett D. Arterial thromboembolism — Epidemiology. In: Haemostasis and Thrombosis — Basic Principles and Clinical Practice 2nd ed. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds). J. B. Lippincott Company; Philadelphia, PA: 1987: 1273 1289
    Google Scholar
  • 3 Epstein FH. The epidemiology of coronary heart disease: A review. J Chronic Dis 1965; 18: 735-774
    CrossrefPubMedGoogle Scholar
  • 4 Rabkin SW, Mathewson FA L, Tate RB. Predicting risk of ischemic heart disease and cerebrovascular disease form systolic and diastolic blood pressure. Ann Intern Med 1978; 88: 342-345
    CrossrefPubMedGoogle Scholar
  • 5 Kannel WB, Castelli WP, Gordon T, McNamara PF. Serum cholesterol, lipoproteins and the risk of coronary heart disease: The Framingham study. Ann Intern Med 1974; 74: 1-12
    PubMedGoogle Scholar
  • 6 Doll R, Peto R. Mortality in relation to smoking: 20 years’ observation on male British doctors. Br Med J 1976; 11: 1525-1536
    PubMedGoogle Scholar
  • 7 Friedman GD, Dales LG, Wry K. Mortality in middle-aged smokers and nonsmokers. N Engl J Med 1977; 300: 213-217
    PubMedGoogle Scholar
  • 8 Pell S, D’Alonzo CA. A three-year study of myocardial infarction in a large employed population. JAMA 1961; 175: 463-470
    CrossrefPubMedGoogle Scholar
  • 9 Kannel WB, McGee DC. Diabetes and cardiovascular risk factors: The Framingham study. Circulation 1979; 59: 8-13
    CrossrefPubMedGoogle Scholar
  • 10 Samama M, Conard J, Horellou MH, Nguyen G, Soria J, VanDreden P. Hypofibrinolysis and thrombosis: state of the art. In: Thrombosis: Diagnosis, Prophylaxis, Therapy Diagnostica Stago Abstract Book; Paris: 1987: 5-9
    Google Scholar
  • 11 Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient tPA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemostas 1987; 57: 67-72
    PubMedGoogle Scholar
  • 12 Juhan-Vague I. Acquired hypofibrinolysis. In: Thrombosis: Diagnosis, Prophylaxis, Therapy Diagnostica Stago Abstract Book; Paris: 1987: 10-14
    Google Scholar
  • 13 Hamsten A, Wiman B, Defair U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
    CrossrefPubMedGoogle Scholar
  • 14 Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 2: 250-253
    PubMedGoogle Scholar
  • 15 Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationship between insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diab Metab 1987; 13: 331-336
    PubMedGoogle Scholar
  • 16 Nilsson IM, Robertson B. Effect of venous occlusion on coagulation and fibrinolytic components in normal subjects. Thromb Diathes Haemorrhag 1968; 20: 397-408
    PubMedGoogle Scholar
  • 17 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (tPA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to tPA. Thromb Haemostas 1985; 54: 684-687
    PubMedGoogle Scholar
  • 18 Contant G, Angles-Cano E, Martinoli JL. A simple and rapid plasminogen activator inhibitor (PAI) assay in plasma, using a unique concentration of tissue plasminogen activator (tPA) and PAI-depleted plasma. Thromb Haemostas 1987; 58: 448 (Abstr 1653)
    PubMedGoogle Scholar
  • 19 Chakrabarti M, Bielawiec JF, Evans JF, Fearnley GR. Methodological study and a recommeded technique for determining the euglobulin lysis time. J Clin Pathol 1968; 21: 698-701
    CrossrefPubMedGoogle Scholar
  • 20 Collen D, Juhan-Vague I. Fibrinolysis and atherosclerosis. Semin Thromb Hemostas 1988; 14: 180-183
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - relationship with plasma insulin. Thromb Haemostas 1989; 61: 370-373
    PubMedGoogle Scholar
  • 22 Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemostas 1988; 60: 491-494
    PubMedGoogle Scholar
  • 23 Ahmad M, Saku K, Glas-Greenwalt P, Kashyap ML. Inhibitor and activator of plasminogen in patients with hyperlipoproteinemias. Thromb Haemostas 1985; 54: 266 (Abstr 1578)
    PubMedGoogle Scholar
  • 24 Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263-268
    CrossrefPubMedGoogle Scholar
  • 25 Hamsten A, Widam B, De Faire U, Blombäck M. Increased plasma levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
    CrossrefPubMedGoogle Scholar
  • 26 Wiman B, Ljungberg B, Chmielewska J, Urden G, Blombäck M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-270
    PubMedGoogle Scholar
  • 27 Nilsson IM, Ljungner H, Tengbom L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: Low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-1456
    CrossrefPubMedGoogle Scholar
  • 28 Paramo JA, De Boer A, Colucci M, Jonker JJ C, Collen D. Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosis. Thromb Haemostas 1985; 54: 725
    PubMedGoogle Scholar
  • 29 Garcia Frada LJ, de la Calle H, Alava I, Navarro JL, Creighton LJ, Gaffney PJ. Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. Thromb Res 1987; 47: 533-540
    CrossrefPubMedGoogle Scholar
  • 30 Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Chakrabarti R, North WR S, Stirling Y. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; 2: 964-966
    CrossrefPubMedGoogle Scholar
  • 31 Hu HH, Chu FL, Wong WJ, Lo YK, Sheng WY. Trends in mortality from cerebrovascular disease in Taiwan. Stroke 1986; 17: 1121-1125
    CrossrefPubMedGoogle Scholar
  • 32 The Taiwan Health Administration. The prevention of cardiac diseases (in Chinese). Health Administ 1987; 7: 18-27
    PubMedGoogle Scholar
  • 33 Shaper AG. Epidemiology of ischaemic heart disease. Med Int 1989; 3: 2808-2813
    PubMedGoogle Scholar
  • 34 Chan CW, Hoaglund FT. Pulmonary thromboebolism and venous thrombosis in Chinese. Clin Orthop 1980; 150: 253-260
    PubMedGoogle Scholar
  • 35 Kemble JV H. Incidence of deep vein thrombosis. Br J Hosp Med 1971; 6: 721-726
    PubMedGoogle Scholar
  • 36 Heatley RV, Hughes LE, Morgan A, Okwonga W. Deep vein thrombosis in a Queensland hospital. Br Med J 1973; 1: 517-519
    CrossrefPubMedGoogle Scholar
  • 37 Nandi P, Wong KP, Wei WI, Ngan H, Ong GB. Incidence of postoperative deep venous thrombosis in Hong Kong Chinese. Br J Surg 1980; 67: 251-253
    CrossrefPubMedGoogle Scholar
  • 38 Cheng KK, Lai ST, Yu TJ, Kuo SM. Postoperative deep vein thrombosis in the Taiwanese Chinese population. Am J Surg 1987; 153: 302-305
    CrossrefPubMedGoogle Scholar
  • 39 Chiu ZH, Chong LL, Lin TC, Ho CH, Lee JY, Yung CH. Comparing the level of contact factors between Chinese and American (in Chinese). Transact Hematol Soc ROC 1987; 56: 68-70
    PubMedGoogle Scholar
  • 40 Schonfeld G. Hypertriglyceridemia in noninsulin dependent diabetes mellitus. Semin Thromb Hemostas 1988; 14: 184-188
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Pan XR, Walden CE, Wamick GR, Hu SX, Albers JJ, Cheung M, Bierman EL. Comparison of plasma lipoproteins and aporoteins in Chinese and American non-insulin-dependent diabetic subjects and controls. Diabetes Care 1986; 9: 395-400
    CrossrefPubMedGoogle Scholar